Market closed

Praxis Precision Medicines/$PRAX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Praxis Precision Medicines

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Ticker

$PRAX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Boston, United States

Employees

82
Website
praxismedicines.com

PRAX Metrics

BasicAdvanced
$1.2B
-
-$9.95
2.69
-

$1.2B

2.69

$81.48

$33.01

324K

13.595

13.496

0.434

0.434

-39.20%

-64.34%

622.712

3.06

3.06

-10.04

-16.93%

-63.00%

-42.41%

What the Analysts think about PRAX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.

PRAX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PRAX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

PRAX News

AllArticlesVideos
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

GlobeNewsWire·2 days ago
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

GlobeNewsWire·4 weeks ago
Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRAX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Praxis Precision Medicines stock?

Praxis Precision Medicines (PRAX) has a market cap of $1.2B as of January 15, 2025.

What is the P/E ratio for Praxis Precision Medicines stock?

The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of January 15, 2025.

Does Praxis Precision Medicines stock pay dividends?

No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Praxis Precision Medicines dividend payment date?

Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Praxis Precision Medicines?

Praxis Precision Medicines (PRAX) has a beta rating of 2.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.